Vitamin D3 Supplementation to Prevent Respiratory Tract Infections
NCT ID: NCT04596657
Last Updated: 2023-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
877 participants
INTERVENTIONAL
2020-10-27
2023-10-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Protocol amendments:
Protocol title was amended to include covid-19. Minimum age was changed from 52 to 18, expanding the sample size. Exclusion criteria re vitamin D intake was changed from \>5000 to \>=5000 IU.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Vitamin D supplementation
Daily vitamin D3 supplementation (5000 IU)
Control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D supplementation
Daily vitamin D3 supplementation (5000 IU)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or older
Exclusion Criteria
* History of nephrolithiasis
* History of intolerance to vitamin D3 supplements
* Use of calcium at a dose \> 600 mg/day (individuals using a dose greater than 600 mg of calcium per day will be asked to limit the amount to 600 mg unless they have been directed by their physician to be taking more than 600 mg/day of calcium. If the latter is true the potential subject will be excluded from the study.)
* Use of vitamin D at a daily dose \> 5000 IU\*
* Use of aluminum-containing phosphate binders in patients with renal failure
* Use of calcipotriene
* Use of digoxin
* Use of thiazide diuretics if using:
* hydrochlorothiazide at a daily dose \> 37.5 mg
* indapamide at a daily dose \> 1.25 mg
* chlorthalidone at a daily dose \> 12.5 mg
* metolazone at a daily dose \> 2.5 mg
* methyclothiazide at a daily dose \> 2.5 mg
* chlorothiazide at a daily dose \> 250 mg
* metolazone at a daily dose \> 0.5 mg
* bendroflumethiazide at a daily dose \> 2.5 mg
* polythiazide at a daily dose \> 1 mg
* hydroflumethiazide at a daily dose \> 25 mg
* Conditions that are associated with a risk of modified vitamin D metabolism
* Known allergy to wool
* Current enrollment in another study
* Life expectancy \<1 month at time of screening
* Cognitive impairment precluding the ability to provide informed consent
* Pregnant or trying to become pregnant
* Employee is team member on the present study
* If potential participants are found to be using vitamin D supplementation upon screening at a daily dose ≤5000 IU/day, they will be eligible for participation by switching to the study dose. If potential participants are taking a multiple vitamin or calcium supplement and there is less than or equal to 800 IU vitamin D in it, they can continue the multivitamin or calcium supplement along with taking the study vitamin D3. Total vitamin D cannot exceed 5,800 IU per day combined between any supplements that contain vitamin D. Use of vitamin D at a daily dose \> 5000 IU at the direction of a physician will be an exclusion criterion. If a potential subject uses over-the-counter vitamin D not directed by a physician at a daily dose \> 5000 IU they will be eligible to participate by switching to the lower study dose.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Won Sook Chung Foundation
UNKNOWN
The Cooper Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cooper University Hospital
Camden, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-455
Identifier Type: -
Identifier Source: org_study_id